Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes
Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12 th week...
Saved in:
| Published in | Archives of virology Vol. 166; no. 4; pp. 1071 - 1081 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Vienna
Springer Vienna
01.04.2021
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0304-8608 1432-8798 1432-8798 |
| DOI | 10.1007/s00705-021-04969-4 |
Cover
| Abstract | Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12
th
week after end of treatment (EOT) by screening for viral genomic RNA in serum and PBMCs with correlation to hepatic parenchymal changes. We recruited 102 out of 2165 patients who had received sofosbuvir/daclatasvir, either alone (n = 1573) or together with ribavirin (n = 592). Subjects were classified into three groups based on testing by single-step reverse transcription PCR: group I, HCV negative in both serum and PBMCs (n = 25); group II, HCV positive in PBMCs only (n = 52); and group III, HCV positive in both serum and PBMCs (n = 25). Groups I and II (n = 77) were selected out of 2102 (every 27
th
subject), while group III (n = 25) were selected from every second or third serologic relapse (n = 63). The pre-sampling population (n = 2165) showed sustained virologic response (SVR) in 33.21%; serologic relapse in 2.91%; HCV RNA only in PBMCs (66.79%) compared to serologic relapses and potential cure (
P
< 0.0001); higher serologic (38 out of 63,
P
= 0.03210) and cellular (36 out of 52,
P
= 0.0002) relapses in dual therapy than in triple therapy. The post-sampling population (n = 102) showed more HCV relapses in dual (50 out of 60) than in triple (27 out of 42) therapy (
P
= 0.0351); increased HCV antisense RNA strand in relapses compared to positive-sense strands alone (
P
< 0.001); and significant SVR events in undetectable (15 out of 31) compared to early (10 out of 55,
P
= 0.0058) and cirrhotic liver tissue changes (0 out of 16,
P
= 0.0006). In summary, HCV treatment with sofosbuvir/daclatasvir is followed by higher rates of serologic and intracellular viral RNA relapse than treatment with sofosbuvir/daclatasvir plus ribavirin. Cellular and serum viral RNA relapses are accompanied by HCV-induced hepatic pathology. An increased SVR with no detectable liver tissue changes was observed after triple therapy due to elimination of HCV RNA from PBMCs. |
|---|---|
| AbstractList | Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12ᵗʰ week after end of treatment (EOT) by screening for viral genomic RNA in serum and PBMCs with correlation to hepatic parenchymal changes. We recruited 102 out of 2165 patients who had received sofosbuvir/daclatasvir, either alone (n = 1573) or together with ribavirin (n = 592). Subjects were classified into three groups based on testing by single-step reverse transcription PCR: group I, HCV negative in both serum and PBMCs (n = 25); group II, HCV positive in PBMCs only (n = 52); and group III, HCV positive in both serum and PBMCs (n = 25). Groups I and II (n = 77) were selected out of 2102 (every 27ᵗʰ subject), while group III (n = 25) were selected from every second or third serologic relapse (n = 63). The pre-sampling population (n = 2165) showed sustained virologic response (SVR) in 33.21%; serologic relapse in 2.91%; HCV RNA only in PBMCs (66.79%) compared to serologic relapses and potential cure (P < 0.0001); higher serologic (38 out of 63, P = 0.03210) and cellular (36 out of 52, P = 0.0002) relapses in dual therapy than in triple therapy. The post-sampling population (n = 102) showed more HCV relapses in dual (50 out of 60) than in triple (27 out of 42) therapy (P = 0.0351); increased HCV antisense RNA strand in relapses compared to positive-sense strands alone (P < 0.001); and significant SVR events in undetectable (15 out of 31) compared to early (10 out of 55, P = 0.0058) and cirrhotic liver tissue changes (0 out of 16, P = 0.0006). In summary, HCV treatment with sofosbuvir/daclatasvir is followed by higher rates of serologic and intracellular viral RNA relapse than treatment with sofosbuvir/daclatasvir plus ribavirin. Cellular and serum viral RNA relapses are accompanied by HCV-induced hepatic pathology. An increased SVR with no detectable liver tissue changes was observed after triple therapy due to elimination of HCV RNA from PBMCs. Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12th week after end of treatment (EOT) by screening for viral genomic RNA in serum and PBMCs with correlation to hepatic parenchymal changes. We recruited 102 out of 2165 patients who had received sofosbuvir/daclatasvir, either alone (n = 1573) or together with ribavirin (n = 592). Subjects were classified into three groups based on testing by single-step reverse transcription PCR: group I, HCV negative in both serum and PBMCs (n = 25); group II, HCV positive in PBMCs only (n = 52); and group III, HCV positive in both serum and PBMCs (n = 25). Groups I and II (n = 77) were selected out of 2102 (every 27th subject), while group III (n = 25) were selected from every second or third serologic relapse (n = 63). The pre-sampling population (n = 2165) showed sustained virologic response (SVR) in 33.21%; serologic relapse in 2.91%; HCV RNA only in PBMCs (66.79%) compared to serologic relapses and potential cure (P < 0.0001); higher serologic (38 out of 63, P = 0.03210) and cellular (36 out of 52, P = 0.0002) relapses in dual therapy than in triple therapy. The post-sampling population (n = 102) showed more HCV relapses in dual (50 out of 60) than in triple (27 out of 42) therapy (P = 0.0351); increased HCV antisense RNA strand in relapses compared to positive-sense strands alone (P < 0.001); and significant SVR events in undetectable (15 out of 31) compared to early (10 out of 55, P = 0.0058) and cirrhotic liver tissue changes (0 out of 16, P = 0.0006). In summary, HCV treatment with sofosbuvir/daclatasvir is followed by higher rates of serologic and intracellular viral RNA relapse than treatment with sofosbuvir/daclatasvir plus ribavirin. Cellular and serum viral RNA relapses are accompanied by HCV-induced hepatic pathology. An increased SVR with no detectable liver tissue changes was observed after triple therapy due to elimination of HCV RNA from PBMCs. Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12 th week after end of treatment (EOT) by screening for viral genomic RNA in serum and PBMCs with correlation to hepatic parenchymal changes. We recruited 102 out of 2165 patients who had received sofosbuvir/daclatasvir, either alone (n = 1573) or together with ribavirin (n = 592). Subjects were classified into three groups based on testing by single-step reverse transcription PCR: group I, HCV negative in both serum and PBMCs (n = 25); group II, HCV positive in PBMCs only (n = 52); and group III, HCV positive in both serum and PBMCs (n = 25). Groups I and II (n = 77) were selected out of 2102 (every 27 th subject), while group III (n = 25) were selected from every second or third serologic relapse (n = 63). The pre-sampling population (n = 2165) showed sustained virologic response (SVR) in 33.21%; serologic relapse in 2.91%; HCV RNA only in PBMCs (66.79%) compared to serologic relapses and potential cure ( P < 0.0001); higher serologic (38 out of 63, P = 0.03210) and cellular (36 out of 52, P = 0.0002) relapses in dual therapy than in triple therapy. The post-sampling population (n = 102) showed more HCV relapses in dual (50 out of 60) than in triple (27 out of 42) therapy ( P = 0.0351); increased HCV antisense RNA strand in relapses compared to positive-sense strands alone ( P < 0.001); and significant SVR events in undetectable (15 out of 31) compared to early (10 out of 55, P = 0.0058) and cirrhotic liver tissue changes (0 out of 16, P = 0.0006). In summary, HCV treatment with sofosbuvir/daclatasvir is followed by higher rates of serologic and intracellular viral RNA relapse than treatment with sofosbuvir/daclatasvir plus ribavirin. Cellular and serum viral RNA relapses are accompanied by HCV-induced hepatic pathology. An increased SVR with no detectable liver tissue changes was observed after triple therapy due to elimination of HCV RNA from PBMCs. Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12th week after end of treatment (EOT) by screening for viral genomic RNA in serum and PBMCs with correlation to hepatic parenchymal changes. We recruited 102 out of 2165 patients who had received sofosbuvir/daclatasvir, either alone (n = 1573) or together with ribavirin (n = 592). Subjects were classified into three groups based on testing by single-step reverse transcription PCR: group I, HCV negative in both serum and PBMCs (n = 25); group II, HCV positive in PBMCs only (n = 52); and group III, HCV positive in both serum and PBMCs (n = 25). Groups I and II (n = 77) were selected out of 2102 (every 27th subject), while group III (n = 25) were selected from every second or third serologic relapse (n = 63). The pre-sampling population (n = 2165) showed sustained virologic response (SVR) in 33.21%; serologic relapse in 2.91%; HCV RNA only in PBMCs (66.79%) compared to serologic relapses and potential cure (P < 0.0001); higher serologic (38 out of 63, P = 0.03210) and cellular (36 out of 52, P = 0.0002) relapses in dual therapy than in triple therapy. The post-sampling population (n = 102) showed more HCV relapses in dual (50 out of 60) than in triple (27 out of 42) therapy (P = 0.0351); increased HCV antisense RNA strand in relapses compared to positive-sense strands alone (P < 0.001); and significant SVR events in undetectable (15 out of 31) compared to early (10 out of 55, P = 0.0058) and cirrhotic liver tissue changes (0 out of 16, P = 0.0006). In summary, HCV treatment with sofosbuvir/daclatasvir is followed by higher rates of serologic and intracellular viral RNA relapse than treatment with sofosbuvir/daclatasvir plus ribavirin. Cellular and serum viral RNA relapses are accompanied by HCV-induced hepatic pathology. An increased SVR with no detectable liver tissue changes was observed after triple therapy due to elimination of HCV RNA from PBMCs.Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12th week after end of treatment (EOT) by screening for viral genomic RNA in serum and PBMCs with correlation to hepatic parenchymal changes. We recruited 102 out of 2165 patients who had received sofosbuvir/daclatasvir, either alone (n = 1573) or together with ribavirin (n = 592). Subjects were classified into three groups based on testing by single-step reverse transcription PCR: group I, HCV negative in both serum and PBMCs (n = 25); group II, HCV positive in PBMCs only (n = 52); and group III, HCV positive in both serum and PBMCs (n = 25). Groups I and II (n = 77) were selected out of 2102 (every 27th subject), while group III (n = 25) were selected from every second or third serologic relapse (n = 63). The pre-sampling population (n = 2165) showed sustained virologic response (SVR) in 33.21%; serologic relapse in 2.91%; HCV RNA only in PBMCs (66.79%) compared to serologic relapses and potential cure (P < 0.0001); higher serologic (38 out of 63, P = 0.03210) and cellular (36 out of 52, P = 0.0002) relapses in dual therapy than in triple therapy. The post-sampling population (n = 102) showed more HCV relapses in dual (50 out of 60) than in triple (27 out of 42) therapy (P = 0.0351); increased HCV antisense RNA strand in relapses compared to positive-sense strands alone (P < 0.001); and significant SVR events in undetectable (15 out of 31) compared to early (10 out of 55, P = 0.0058) and cirrhotic liver tissue changes (0 out of 16, P = 0.0006). In summary, HCV treatment with sofosbuvir/daclatasvir is followed by higher rates of serologic and intracellular viral RNA relapse than treatment with sofosbuvir/daclatasvir plus ribavirin. Cellular and serum viral RNA relapses are accompanied by HCV-induced hepatic pathology. An increased SVR with no detectable liver tissue changes was observed after triple therapy due to elimination of HCV RNA from PBMCs. Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12 week after end of treatment (EOT) by screening for viral genomic RNA in serum and PBMCs with correlation to hepatic parenchymal changes. We recruited 102 out of 2165 patients who had received sofosbuvir/daclatasvir, either alone (n = 1573) or together with ribavirin (n = 592). Subjects were classified into three groups based on testing by single-step reverse transcription PCR: group I, HCV negative in both serum and PBMCs (n = 25); group II, HCV positive in PBMCs only (n = 52); and group III, HCV positive in both serum and PBMCs (n = 25). Groups I and II (n = 77) were selected out of 2102 (every 27 subject), while group III (n = 25) were selected from every second or third serologic relapse (n = 63). The pre-sampling population (n = 2165) showed sustained virologic response (SVR) in 33.21%; serologic relapse in 2.91%; HCV RNA only in PBMCs (66.79%) compared to serologic relapses and potential cure (P < 0.0001); higher serologic (38 out of 63, P = 0.03210) and cellular (36 out of 52, P = 0.0002) relapses in dual therapy than in triple therapy. The post-sampling population (n = 102) showed more HCV relapses in dual (50 out of 60) than in triple (27 out of 42) therapy (P = 0.0351); increased HCV antisense RNA strand in relapses compared to positive-sense strands alone (P < 0.001); and significant SVR events in undetectable (15 out of 31) compared to early (10 out of 55, P = 0.0058) and cirrhotic liver tissue changes (0 out of 16, P = 0.0006). In summary, HCV treatment with sofosbuvir/daclatasvir is followed by higher rates of serologic and intracellular viral RNA relapse than treatment with sofosbuvir/daclatasvir plus ribavirin. Cellular and serum viral RNA relapses are accompanied by HCV-induced hepatic pathology. An increased SVR with no detectable liver tissue changes was observed after triple therapy due to elimination of HCV RNA from PBMCs. |
| Author | Farrag, Galal Ammar, Islam Abdelmawla Emran Dawood, Reham M. Rashed, Hassan Abd EL-Hafeth Altanbouly, Ahmed Mohamed Abdulhamid Abd Alla, Mohamed Darwish Ahmed Mahmoud, Mohamed Mahmoud Abdel-Halim Awady, Mostafa K. El Salum, Ghada M. El Meguid, Mai A. |
| Author_xml | – sequence: 1 givenname: Mohamed Darwish Ahmed orcidid: 0000-0002-3601-6907 surname: Abd Alla fullname: Abd Alla, Mohamed Darwish Ahmed email: darwish0716@azhar.edu.eg organization: Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University – sequence: 2 givenname: Reham M. surname: Dawood fullname: Dawood, Reham M. organization: Department of Microbial Biotechnology, National Research Center – sequence: 3 givenname: Hassan Abd EL-Hafeth surname: Rashed fullname: Rashed, Hassan Abd EL-Hafeth organization: Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University – sequence: 4 givenname: Galal surname: Farrag fullname: Farrag, Galal organization: Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University – sequence: 5 givenname: Islam Abdelmawla Emran surname: Ammar fullname: Ammar, Islam Abdelmawla Emran organization: Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University – sequence: 6 givenname: Mohamed Mahmoud Abdel-Halim surname: Mahmoud fullname: Mahmoud, Mohamed Mahmoud Abdel-Halim organization: Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University – sequence: 7 givenname: Ghada M. surname: Salum fullname: Salum, Ghada M. organization: Department of Microbial Biotechnology, National Research Center – sequence: 8 givenname: Ahmed Mohamed Abdulhamid surname: Altanbouly fullname: Altanbouly, Ahmed Mohamed Abdulhamid organization: Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University – sequence: 9 givenname: Mai A. surname: El Meguid fullname: El Meguid, Mai A. organization: Department of Microbial Biotechnology, National Research Center – sequence: 10 givenname: Mostafa K. El surname: Awady fullname: Awady, Mostafa K. El organization: Department of Microbial Biotechnology, National Research Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33533976$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1u1TAQhS1URG8LL8ACWWLDJuDYTuwsqyv-pAokVNaRrzO5cZXYwXaK-qS8DpOmgNRF2Tj26DuTM5pzRk588EDIy5K9LRlT7xIerCoYLwsmm7op5BOyK6XghVaNPiE7JpgsdM30KTlL6ZoxLIjqGTkVohKiUfWO_LqKYPIEPtPQ0wFmk112ie7pjYtLos73YLMLnv50eaCdi_gsDJb8kRqfHWJmTHQeEY7uYPDtPIXRTc6bDIneAfTblwvaxzDRGaKbB1hrhzGEjk4Bx1rsCCZSCyP2Mr6jEbrFbuowhqOzWBnNnAAdoYsbiHjd7Fo6mwjeDrcTNrWD8UdIz8nTHn3Bi_vvOfn-4f3V_lNx-fXj5_3FZWEl07ngnVYKLNOSlRWv-95aAFCWV0xXWmlmetMx2Xemq5k1xpbiICUvFXBuQFpxTt5sfecYfiyQcju5tI5hPIQltbyqyqZhCtfyX1Tquqw05xzR1w_Q67BEj4NgQ8ZKpYRcqVf31HKYoGvn6CYTb9s_20WAb4CNIaUI_V-kZO0aoXaLUIsRau8i1K429QORddmsEcjRuPFxqdikCf-DW4j_bD-i-g0hNOAZ |
| CitedBy_id | crossref_primary_10_1186_s43141_023_00544_3 crossref_primary_10_4103_bbrj_bbrj_209_21 crossref_primary_10_1016_j_heliyon_2023_e21194 crossref_primary_10_1016_j_cca_2024_120013 crossref_primary_10_1016_j_heliyon_2022_e10119 crossref_primary_10_1016_j_cyto_2024_156714 crossref_primary_10_1186_s43141_021_00266_4 |
| Cites_doi | 10.1371/journal.pone.0101760 10.1186/1743-422X-10-346 10.5812/hepatmon.44564 10.1016/j.cgh.2017.09.027 10.21608/zumj.2017.41211 10.1016/j.jhep.2015.04.023 10.1016/S0168-8278(18)30769-4 10.1046/j.1440-1746.2003.02919.x 10.1111/apt.13541 10.1111/liv.13266 10.1111/liv.13727 10.1111/liv.13319 10.1111/apt.13095 10.1016/j.jhep.2014.12.031 10.1053/j.gastro.2016.04.003 10.1023/A:1018888021118 10.1002/jmv.21866 10.1016/j.cgh.2014.12.014 10.1007/s15010-016-0962-3 10.1016/j.jhep.2014.10.044 10.14218/JCTH.2017.00077 10.1111/jgh.14815 10.1053/j.gastro.2015.05.010 10.1016/S2468-1253(16)30002-4 10.1016/j.jhep.2017.03.039 10.1016/S1473-3099(15)00157-7 10.1016/S1473-3099(17)30496-6 10.1016/S0009-8981(99)00007-8 10.1056/NEJMoa1512610 10.1016/j.ajme.2013.05.004 10.1080/17512433.2016.1233813 10.1016/0003-2697(87)90021-2 10.4103/AZMJ.AZMJ_22_18 10.1002/hep.24262 10.1136/gutjnl-2014-307498 10.14218/JCTH.2017.00034 10.1086/380202 10.1002/hep.27726 10.1016/S0140-6736(15)60159-3 10.1002/hep.20935 10.1053/j.gastro.2016.05.049 10.1136/bmjgast-2016-000112 10.1016/j.jhep.2017.01.028 10.21608/jesp.2017.77783 10.1111/liv.13212 10.1002/hep.28706 10.1053/j.gastro.2014.09.023 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature 2021 The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature 2021. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature 2021 – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7TM 7U9 7X7 7XB 88A 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 7S9 L.6 |
| DOI | 10.1007/s00705-021-04969-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA ProQuest Central Student MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1432-8798 |
| EndPage | 1081 |
| ExternalDocumentID | 33533976 10_1007_s00705_021_04969_4 |
| Genre | Journal Article |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C -~X .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 23N 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67N 67Z 6NX 78A 7X7 88A 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X A8Z AAAVM AABHQ AACDK AAHBH AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BPHCQ BSONS BVXVI CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LK8 LLZTM M0L M1P M4Y M7P MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 Y6R YLTOR Z45 Z7U Z7V Z7W Z7Y Z82 Z83 Z87 Z8O Z8P Z8Q Z8S Z8V Z8W Z91 Z92 ZGI ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7TK 7TM 7U9 7XB 8FD 8FK ABRTQ AZQEC DWQXO FR3 GNUQQ H94 K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS PUEGO RC3 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c408t-2d877ec08401526ffcceee7c250858780afad04fdad60caac13b44217e22ae4c3 |
| IEDL.DBID | 7X7 |
| ISSN | 0304-8608 1432-8798 |
| IngestDate | Thu Sep 04 21:31:41 EDT 2025 Thu Sep 04 16:39:43 EDT 2025 Sat Aug 23 14:55:29 EDT 2025 Thu Apr 03 06:52:25 EDT 2025 Tue Jul 01 02:42:59 EDT 2025 Thu Apr 24 22:56:05 EDT 2025 Fri Feb 21 02:48:51 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c408t-2d877ec08401526ffcceee7c250858780afad04fdad60caac13b44217e22ae4c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-3601-6907 |
| PMID | 33533976 |
| PQID | 2500177342 |
| PQPubID | 48320 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2551990714 proquest_miscellaneous_2486158222 proquest_journals_2500177342 pubmed_primary_33533976 crossref_primary_10_1007_s00705_021_04969_4 crossref_citationtrail_10_1007_s00705_021_04969_4 springer_journals_10_1007_s00705_021_04969_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20210400 2021-04-00 2021-Apr 20210401 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 4 year: 2021 text: 20210400 |
| PublicationDecade | 2020 |
| PublicationPlace | Vienna |
| PublicationPlace_xml | – name: Vienna – name: Austria – name: Wien |
| PublicationSubtitle | Official Journal of the Virology Division of the International Union of Microbiological Societies |
| PublicationTitle | Archives of virology |
| PublicationTitleAbbrev | Arch Virol |
| PublicationTitleAlternate | Arch Virol |
| PublicationYear | 2021 |
| Publisher | Springer Vienna Springer Nature B.V |
| Publisher_xml | – name: Springer Vienna – name: Springer Nature B.V |
| References | Ruane, Ain, Stryker, Meshrekey (CR1) 2015; 62 Ioannou, Beste, Chang (CR48) 2016; 151 Doss, Shiha, Hassany, Soliman (CR2) 2015; 63 Hézode, Hirschfield, Ghesquiere, Sievert (CR5) 2015; 64 Zeng, Li, Zhang (CR46) 2016; 43 Reedy, Loo, Levine (CR35) 1998; 43 Eletreby, Elakel, El Raziky, Esmat (CR4) 2017; 37 Abd Alla, Elibiary, Elshaboury (CR42) 2018; 6 Pawełczyk, Kubisa, Jabłońska (CR40) 2013; 10 Chomczyński, Sacchi (CR37) 1987; 162 Calleja, CrespoJ (CR32) 2017; 66 El-Awady, Ismail, El-Sagheer (CR41) 1999; 283 Abd Alla, Gomaa, Farrag (CR43) 2018; 16 Calès, Oberti, Michalak, Hubert-Fouchard (CR34) 2005; 42 Moreno, Hezode, Marcellin, Bourgeois (CR6) 2015; 62 Forns, Lee, Valdes, Lens, Ghalib, Aguilar (CR7) 2017; 17 Kwo, Poordad, Asatryan, Wang, Wyles (CR10) 2017; 67 Elzahaby, Soliman, Korany (CR39) 2017; 47 Waked, Shiha, Qaqish, Esmat (CR15) 2016; 1 Soliman, Negm, Elzalabany, Malik (CR20) 2018; 68 Huang, Yeh, Huang (CR44) 2020; 35 Asselah, Kowdley, Zadeikis (CR8) 2018; 16 Abergel, Metivier, Samuel, Jiang (CR14) 2016; 64 El Kassas, Elbaz, Abd El Latif, Esmat (CR12) 2016; 9 Feld, Jacobson, Sulkowski, Poordad, Tatsch, Pawlotsky (CR17) 2017; 37 Castillo, Pardo, Bartolomé (CR25) 2004; 189 Hanno, Mohiedeen, Alshayeb, Deghedy (CR23) 2014; 50 El-Awady, Abdel Rahman, Ismail, Amr, Omran (CR38) 2003; 18 Boglione, Pinna, Cardellino (CR50) 2017; 45 Nelson, Cooper, Lalezari, Lawitz (CR47) 2015; 61 Feld, Jacobson, Hézode, Asselah (CR9) 2015; 373 Castillo, Bartolomé, Quiroga, Barril, Carreño (CR24) 2010; 82 Kohli, Kapoor, Sims, Nelson (CR13) 2015; 15 Merat, Sharifi, Haj-Sheykholeslami (CR51) 2017; 17 Asselah, Reesink, Gerstoft, de Ledinghen (CR11) 2018; 38 Eletreby, Elakel, Said, El Kassas (CR3) 2017; 37 Corchado, López, Rivero (CR30) 2014; 9 Sterling, Kuo, Rustgi (CR49) 2015; 41 Pawlosky (CR29) 2016; 151 Salama, Zekri, Medhat (CR22) 2016; 1 Abd Alla, El Awady (CR26) 2017; 5 Pawlosky (CR31) 2011; 53 Abd Alla, Elibiary, Wu, El-Awady (CR27) 2017; 5 Abd Alla, El Awady, Dawood, Elhawary (CR28) 2018; 163 Curry, Forns, Chung, Terrault (CR18) 2015; 148 Hathorn, Elsharkawy (CR21) 2016; 3 Elsharkawy, Hashem, Fouad, Negm (CR45) 2017; 5 Charlton, Everson, Flamm, Kumar (CR19) 2015; 149 Afdhal, BaconBR, Lawitz (CR33) 2015; 13 Hézode, Asselah, Reddy, Hassanein (CR16) 2015; 385 Wahab, Fathy, Saber, Ahmad (CR36) 2017; 21 S Corchado (4969_CR30) 2014; 9 MDA Abd Alla (4969_CR26) 2017; 5 A Pawełczyk (4969_CR40) 2013; 10 MDA Abd Alla (4969_CR43) 2018; 16 CF Huang (4969_CR44) 2020; 35 S Merat (4969_CR51) 2017; 17 MDA Abd Alla (4969_CR28) 2018; 163 T Asselah (4969_CR8) 2018; 16 PY Kwo (4969_CR10) 2017; 67 L Boglione (4969_CR50) 2017; 45 C Hézode (4969_CR16) 2015; 385 M El Kassas (4969_CR12) 2016; 9 A Abergel (4969_CR14) 2016; 64 A Elsharkawy (4969_CR45) 2017; 5 I Castillo (4969_CR25) 2004; 189 JJ Feld (4969_CR9) 2015; 373 T Asselah (4969_CR11) 2018; 38 H Salama (4969_CR22) 2016; 1 C Hézode (4969_CR5) 2015; 64 R Eletreby (4969_CR4) 2017; 37 DW Reedy (4969_CR35) 1998; 43 DR Nelson (4969_CR47) 2015; 61 RK Sterling (4969_CR49) 2015; 41 JM Pawlosky (4969_CR31) 2011; 53 M Charlton (4969_CR19) 2015; 149 X Forns (4969_CR7) 2017; 17 AF Hanno (4969_CR23) 2014; 50 AA Elzahaby (4969_CR39) 2017; 47 JM Pawlosky (4969_CR29) 2016; 151 P Chomczyński (4969_CR37) 1987; 162 QL Zeng (4969_CR46) 2016; 43 NH Afdhal (4969_CR33) 2015; 13 JL Calleja (4969_CR32) 2017; 66 MDA Abd Alla (4969_CR42) 2018; 6 R Eletreby (4969_CR3) 2017; 37 I Waked (4969_CR15) 2016; 1 MK El-Awady (4969_CR38) 2003; 18 E Hathorn (4969_CR21) 2016; 3 C Moreno (4969_CR6) 2015; 62 G Soliman (4969_CR20) 2018; 68 PJ Ruane (4969_CR1) 2015; 62 A Kohli (4969_CR13) 2015; 15 MK El-Awady (4969_CR41) 1999; 283 I Castillo (4969_CR24) 2010; 82 MP Curry (4969_CR18) 2015; 148 JJ Feld (4969_CR17) 2017; 37 MDA Abd Alla (4969_CR27) 2017; 5 W Doss (4969_CR2) 2015; 63 GN Ioannou (4969_CR48) 2016; 151 P Calès (4969_CR34) 2005; 42 EA Wahab (4969_CR36) 2017; 21 |
| References_xml | – volume: 385 start-page: 2502 issue: 9986 year: 2015 end-page: 2509 ident: CR16 article-title: Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial publication-title: Lancet – volume: 43 start-page: 842 year: 2016 end-page: 843 ident: CR46 article-title: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV publication-title: Aliment Pharm Ther – volume: 15 start-page: 1049 issue: 9 year: 2015 end-page: 1054 ident: CR13 article-title: Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study publication-title: Lancet Infect Dis – volume: 67 start-page: 263 issue: 2 year: 2017 end-page: 271 ident: CR10 article-title: Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis publication-title: J Hepatol – volume: 9 start-page: 1413 issue: 11 year: 2016 end-page: 1421 ident: CR12 article-title: Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4 publication-title: Expert Rev Clin Pharmacol – volume: 21 start-page: 1 year: 2017 end-page: 11 ident: CR36 article-title: Hepatic elastography and fib-4 score versus liver biopsy for assessment of liver fibrosis in chronic Hcv patients publication-title: Zagazig Univ Med J – volume: 35 start-page: 151 issue: 1 year: 2020 end-page: 156 ident: CR44 article-title: Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir publication-title: J Gastroenterol Hepatol – volume: 64 start-page: 948 issue: 6 year: 2015 end-page: 956 ident: CR5 article-title: Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study publication-title: Gut – volume: 5 start-page: 319 year: 2017 end-page: 326 ident: CR27 article-title: Occult HCV infection (OCI) diagnosis in cirrhotic and non-cirrhotic naïve patients by intra-PBMC nested viral rNA PCR publication-title: J Clin Transl Hepatol – volume: 43 start-page: 2156 year: 1998 end-page: 2159 ident: CR35 article-title: AST/ALT ratio ≥ 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C publication-title: Dig Dis Sci – volume: 1 start-page: 36 issue: 1 year: 2016 end-page: 44 ident: CR15 article-title: Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial publication-title: Lancet Gastroenterol Hepatol – volume: 9 start-page: e101760 issue: 7 year: 2014 ident: CR30 article-title: Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients publication-title: PLoS One doi: 10.1371/journal.pone.0101760 – volume: 64 start-page: 1049 issue: 4 year: 2016 end-page: 1056 ident: CR14 article-title: Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection publication-title: Hepatology – volume: 148 start-page: 100 issue: 1 year: 2015 end-page: 107 ident: CR18 article-title: Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study publication-title: Gastroenterology – volume: 38 start-page: 1583 issue: 9 year: 2018 end-page: 1591 ident: CR11 article-title: Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis publication-title: Liver Int – volume: 10 start-page: 346 issue: 1 year: 2013 ident: CR40 article-title: Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+ publication-title: Virol J doi: 10.1186/1743-422X-10-346 – volume: 163 start-page: 2765 issue: 10 year: 2018 end-page: 2774 ident: CR28 article-title: Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis publication-title: Adv Virol – volume: 1 start-page: 143 year: 2016 end-page: 153 ident: CR22 article-title: Sofosbuvir plus daclatasvir with fixed versus weight adjusted dose of ribavirin for treatment of HCV genotype 4 among Egyptian patients publication-title: EC Gastroenterol Dig Syst – volume: 62 start-page: 1047 issue: 5 year: 2015 end-page: 1055 ident: CR6 article-title: Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4 publication-title: J Hepatol – volume: 162 start-page: 156 year: 1987 end-page: 159 ident: CR37 article-title: Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chlotoform extraction publication-title: Anal Biochem – volume: 47 start-page: 323 year: 2017 end-page: 330 ident: CR39 article-title: Association between post treatment existence Of HCV/RNA positive strand and/or negative strand in the PBMCs and HCV relapse publication-title: J Egypt Soc Parasitol – volume: 5 start-page: 1 year: 2017 end-page: 8 ident: CR26 article-title: Hepatitis C virus RNA strands detection in peripheral blood mononuclear cells legitimizes virus eradication in negative serum PCR naïve and post-treatment patients publication-title: J Clin Transl Hepatol – volume: 53 start-page: 1742 year: 2011 end-page: 1751 ident: CR31 article-title: Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus publication-title: Hepatology – volume: 63 start-page: 581 issue: 3 year: 2015 end-page: 585 ident: CR2 article-title: Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4 publication-title: J Hepatol – volume: 149 start-page: 649 issue: 3 year: 2015 end-page: 659 ident: CR19 article-title: Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease publication-title: Gastroenterology – volume: 16 start-page: 417 issue: 3 year: 2018 end-page: 426 ident: CR8 article-title: Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with HCV genotype 2,4,5, or 6 infection without cirrhosis publication-title: Clin Gastroenterol Hepatol – volume: 5 start-page: 209 year: 2017 end-page: 213 ident: CR45 article-title: Safety and efficacy of the generic products of sofosbuvir and daclatasvir in treatment of HCV genotype 4 Egyptian patients publication-title: Merit Res J Med Med Sci – volume: 61 start-page: 1127 issue: 4 year: 2015 end-page: 1135 ident: CR47 article-title: All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study publication-title: Hepatology – volume: 66 start-page: 1138 issue: 6 year: 2017 end-page: 1148 ident: CR32 article-title: Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in Hepatitis C Virus genotype 1 infection: results from a Spanish real-world cohort publication-title: J of hepatology – volume: 17 start-page: e44564 issue: 1 year: 2017 ident: CR51 article-title: The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3 publication-title: Hepat Mon doi: 10.5812/hepatmon.44564 – volume: 189 start-page: 7 issue: 1 year: 2004 end-page: 14 ident: CR25 article-title: Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown publication-title: J Infect Dis – volume: 151 start-page: 457 issue: 3 year: 2016 end-page: 471 ident: CR48 article-title: Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System publication-title: Gastroenterology – volume: 6 start-page: 1 issue: 2 year: 2018 end-page: 8 ident: CR42 article-title: HCV therapy follow-up fractionation (CTF2) by intra-PBMC nested RNA PCR recognizes early virologic response and relapse publication-title: J Clin Trans Hepatol – volume: 18 start-page: 68 year: 2003 end-page: 7339 ident: CR38 article-title: Prediction of relapse after interferon therapy in hepatitis C virus-infected patients by the use of triple assay publication-title: J Gastroenterol Hepatol – volume: 151 start-page: 70 year: 2016 end-page: 86 ident: CR29 article-title: Hepatitis C virus resistance to direct-acting antiviral drugs in interferon free regimens publication-title: Gastroenterology – volume: 62 start-page: 1040 issue: 5 year: 2015 end-page: 1046 ident: CR1 article-title: Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry publication-title: J Hepatol – volume: 37 start-page: 766 year: 2017 end-page: 766 ident: CR4 article-title: Response to Real life Egyptian experience of efficacy/safety of Simeprevir\Sofosbuvir in HCV genotype IV publication-title: Liver Int – volume: 68 start-page: S276 year: 2018 ident: CR20 article-title: Is treatment of hepatitis C with controlled generic direct acting antiviral drugs effective? An Egyptian experience publication-title: J Hepatol – volume: 82 start-page: 1554 year: 2010 end-page: 1559 ident: CR24 article-title: Diagnosis of occult hepatitis C without the need for a liver biopsy publication-title: J Med Virol – volume: 41 start-page: 671 issue: 7 year: 2015 end-page: 685 ident: CR49 article-title: Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir publication-title: Aliment Pharm Ther – volume: 283 start-page: 1 issue: 1–2 year: 1999 end-page: 14 ident: CR41 article-title: Assay for hepatitis C virus in peripheral blood mononuclear cells enhances sensitivity of diagnosis and monitoring of HCV-associated hepatitis publication-title: Clin Chim Acta – volume: 45 start-page: 103 issue: 1 year: 2017 end-page: 106 ident: CR50 article-title: Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors publication-title: Infection – volume: 37 start-page: 534 issue: 4 year: 2017 end-page: 541 ident: CR3 article-title: Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients publication-title: Liver Int – volume: 37 start-page: 5 issue: 1 year: 2017 end-page: 18 ident: CR17 article-title: Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection publication-title: Liver Int – volume: 42 start-page: 1373 issue: 6 year: 2005 end-page: 1381 ident: CR34 article-title: A novel panel of blood markers to assess the degree of liver fibrosis publication-title: Hepatology – volume: 373 start-page: 2599 issue: 27 year: 2015 end-page: 2607 ident: CR9 article-title: Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection publication-title: N Engl J Med – volume: 50 start-page: 317 issue: 4 year: 2014 end-page: 322 ident: CR23 article-title: HCV RNA in peripheral blood mononuclear cells (PBMCs) as a predictor of the response to antiviral therapy in chronic hepatitis C publication-title: Alex J Med – volume: 17 start-page: 1062 issue: 10 year: 2017 end-page: 1068 ident: CR7 article-title: Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial publication-title: Lancet Infect Dis – volume: 16 start-page: 197 issue: 2 year: 2018 end-page: 204 ident: CR43 article-title: Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin publication-title: Al-Azhar Assiut Med J – volume: 3 start-page: e000112 issue: 1 year: 2016 ident: CR21 article-title: Management of hepatitis C genotype 4 in the directly acting antivirals era publication-title: BMJ Open Gastroenterol – volume: 13 start-page: 772 issue: 4 year: 2015 end-page: 779 ident: CR33 article-title: Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study publication-title: Clin Gastroenterol Hepatol – volume: 16 start-page: 417 issue: 3 year: 2018 ident: 4969_CR8 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2017.09.027 – volume: 21 start-page: 1 year: 2017 ident: 4969_CR36 publication-title: Zagazig Univ Med J doi: 10.21608/zumj.2017.41211 – volume: 63 start-page: 581 issue: 3 year: 2015 ident: 4969_CR2 publication-title: J Hepatol doi: 10.1016/j.jhep.2015.04.023 – volume: 68 start-page: S276 year: 2018 ident: 4969_CR20 publication-title: J Hepatol doi: 10.1016/S0168-8278(18)30769-4 – volume: 18 start-page: 68 year: 2003 ident: 4969_CR38 publication-title: J Gastroenterol Hepatol doi: 10.1046/j.1440-1746.2003.02919.x – volume: 43 start-page: 842 year: 2016 ident: 4969_CR46 publication-title: Aliment Pharm Ther doi: 10.1111/apt.13541 – volume: 37 start-page: 534 issue: 4 year: 2017 ident: 4969_CR3 publication-title: Liver Int doi: 10.1111/liv.13266 – volume: 38 start-page: 1583 issue: 9 year: 2018 ident: 4969_CR11 publication-title: Liver Int doi: 10.1111/liv.13727 – volume: 1 start-page: 143 year: 2016 ident: 4969_CR22 publication-title: EC Gastroenterol Dig Syst – volume: 37 start-page: 766 year: 2017 ident: 4969_CR4 publication-title: Liver Int doi: 10.1111/liv.13319 – volume: 41 start-page: 671 issue: 7 year: 2015 ident: 4969_CR49 publication-title: Aliment Pharm Ther doi: 10.1111/apt.13095 – volume: 62 start-page: 1047 issue: 5 year: 2015 ident: 4969_CR6 publication-title: J Hepatol doi: 10.1016/j.jhep.2014.12.031 – volume: 151 start-page: 70 year: 2016 ident: 4969_CR29 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.04.003 – volume: 43 start-page: 2156 year: 1998 ident: 4969_CR35 publication-title: Dig Dis Sci doi: 10.1023/A:1018888021118 – volume: 82 start-page: 1554 year: 2010 ident: 4969_CR24 publication-title: J Med Virol doi: 10.1002/jmv.21866 – volume: 13 start-page: 772 issue: 4 year: 2015 ident: 4969_CR33 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.12.014 – volume: 45 start-page: 103 issue: 1 year: 2017 ident: 4969_CR50 publication-title: Infection doi: 10.1007/s15010-016-0962-3 – volume: 9 start-page: e101760 issue: 7 year: 2014 ident: 4969_CR30 publication-title: PLoS One doi: 10.1371/journal.pone.0101760 – volume: 62 start-page: 1040 issue: 5 year: 2015 ident: 4969_CR1 publication-title: J Hepatol doi: 10.1016/j.jhep.2014.10.044 – volume: 6 start-page: 1 issue: 2 year: 2018 ident: 4969_CR42 publication-title: J Clin Trans Hepatol doi: 10.14218/JCTH.2017.00077 – volume: 35 start-page: 151 issue: 1 year: 2020 ident: 4969_CR44 publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.14815 – volume: 149 start-page: 649 issue: 3 year: 2015 ident: 4969_CR19 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.05.010 – volume: 1 start-page: 36 issue: 1 year: 2016 ident: 4969_CR15 publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(16)30002-4 – volume: 10 start-page: 346 issue: 1 year: 2013 ident: 4969_CR40 publication-title: Virol J doi: 10.1186/1743-422X-10-346 – volume: 67 start-page: 263 issue: 2 year: 2017 ident: 4969_CR10 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.039 – volume: 15 start-page: 1049 issue: 9 year: 2015 ident: 4969_CR13 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00157-7 – volume: 17 start-page: 1062 issue: 10 year: 2017 ident: 4969_CR7 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30496-6 – volume: 283 start-page: 1 issue: 1–2 year: 1999 ident: 4969_CR41 publication-title: Clin Chim Acta doi: 10.1016/S0009-8981(99)00007-8 – volume: 373 start-page: 2599 issue: 27 year: 2015 ident: 4969_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa1512610 – volume: 50 start-page: 317 issue: 4 year: 2014 ident: 4969_CR23 publication-title: Alex J Med doi: 10.1016/j.ajme.2013.05.004 – volume: 9 start-page: 1413 issue: 11 year: 2016 ident: 4969_CR12 publication-title: Expert Rev Clin Pharmacol doi: 10.1080/17512433.2016.1233813 – volume: 162 start-page: 156 year: 1987 ident: 4969_CR37 publication-title: Anal Biochem doi: 10.1016/0003-2697(87)90021-2 – volume: 16 start-page: 197 issue: 2 year: 2018 ident: 4969_CR43 publication-title: Al-Azhar Assiut Med J doi: 10.4103/AZMJ.AZMJ_22_18 – volume: 53 start-page: 1742 year: 2011 ident: 4969_CR31 publication-title: Hepatology doi: 10.1002/hep.24262 – volume: 64 start-page: 948 issue: 6 year: 2015 ident: 4969_CR5 publication-title: Gut doi: 10.1136/gutjnl-2014-307498 – volume: 5 start-page: 1 year: 2017 ident: 4969_CR26 publication-title: J Clin Transl Hepatol doi: 10.14218/JCTH.2017.00034 – volume: 163 start-page: 2765 issue: 10 year: 2018 ident: 4969_CR28 publication-title: Adv Virol – volume: 189 start-page: 7 issue: 1 year: 2004 ident: 4969_CR25 publication-title: J Infect Dis doi: 10.1086/380202 – volume: 61 start-page: 1127 issue: 4 year: 2015 ident: 4969_CR47 publication-title: Hepatology doi: 10.1002/hep.27726 – volume: 5 start-page: 209 year: 2017 ident: 4969_CR45 publication-title: Merit Res J Med Med Sci – volume: 385 start-page: 2502 issue: 9986 year: 2015 ident: 4969_CR16 publication-title: Lancet doi: 10.1016/S0140-6736(15)60159-3 – volume: 5 start-page: 319 year: 2017 ident: 4969_CR27 publication-title: J Clin Transl Hepatol – volume: 42 start-page: 1373 issue: 6 year: 2005 ident: 4969_CR34 publication-title: Hepatology doi: 10.1002/hep.20935 – volume: 151 start-page: 457 issue: 3 year: 2016 ident: 4969_CR48 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.05.049 – volume: 3 start-page: e000112 issue: 1 year: 2016 ident: 4969_CR21 publication-title: BMJ Open Gastroenterol doi: 10.1136/bmjgast-2016-000112 – volume: 66 start-page: 1138 issue: 6 year: 2017 ident: 4969_CR32 publication-title: J of hepatology doi: 10.1016/j.jhep.2017.01.028 – volume: 47 start-page: 323 year: 2017 ident: 4969_CR39 publication-title: J Egypt Soc Parasitol doi: 10.21608/jesp.2017.77783 – volume: 37 start-page: 5 issue: 1 year: 2017 ident: 4969_CR17 publication-title: Liver Int doi: 10.1111/liv.13212 – volume: 64 start-page: 1049 issue: 4 year: 2016 ident: 4969_CR14 publication-title: Hepatology doi: 10.1002/hep.28706 – volume: 148 start-page: 100 issue: 1 year: 2015 ident: 4969_CR18 publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.09.023 – volume: 17 start-page: e44564 issue: 1 year: 2017 ident: 4969_CR51 publication-title: Hepat Mon doi: 10.5812/hepatmon.44564 |
| SSID | ssj0003035 |
| Score | 2.36584 |
| Snippet | Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1071 |
| SubjectTerms | Adult Antisense RNA Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs Biomedical and Life Sciences Biomedicine blood serum Carbamates - therapeutic use Complications complications (disease) Drug Therapy, Combination Female genomics genotype Genotypes Hepacivirus - drug effects Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - pathology Hepatitis C, Chronic - virology Humans Imidazoles - therapeutic use Infectious Diseases Interferon Leukocytes (mononuclear) Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - virology Liver Liver - drug effects Liver - pathology Male Medical Microbiology Middle Aged Original Article Parenchymal Tissue - drug effects Parenchymal Tissue - pathology Peripheral blood mononuclear cells Pyrrolidines - therapeutic use relapse reverse transcriptase polymerase chain reaction Reverse transcription Ribavirin Ribavirin - therapeutic use Ribonucleic acid RNA RNA, Viral - analysis RNA, Viral - drug effects Sampling Secondary Prevention Sofosbuvir - therapeutic use therapeutics Treatment Outcome Valine - analogs & derivatives Valine - therapeutic use Virology |
| SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwEB3BVkhcyjcEChokbpAqH07iHFdVSwWiB9SVyilyHIdGhOwqyVYqf5S_w0ycBEGhUo9RJtZ4PR4_r988A7wpCQPQOsdlvzTJRUB7VpWmxpW5FlLrWEeDTsGnk_h4JT6cRWdjUVg3sd2nI8khU8_FbqxMw9XEtP0VaZy64jbsRL5M5QJ2lu-_fDycMzCl5cieHghXxp4ci2X-3cqfC9IVlHnlhHRYeI7uwWpy2fJNvu1v-3xf__hLzfGmfboPuyMSxaUNnQdwyzQP4Y69m_LyEfw8nSjouC7x3DDzuq86PMCLqt12OLG4GuS_ctEujS6XSTRfkYarYvZw3eGmJuO2yhU9Vw2aerhGjAAuDgb4-WSJXOOCLLk8aBzUOLDpkSbIumG5ZdUiny901GyBLWvN2q9t3kYux9l0hjwiL5hlYkZ3NTK9vtHnl9-pUVvi3D2G1dHh6cGxO94C4Wrhyd4NCpkkRnu0EyWsEZelpnXdJJqwm4xkIj1VqsITZaGK2NNKaT_MhaCdlgkCZYQOn8CC3DXPAFMykkmYlyrxRV4IlTA1T8UmNLks49IBfwqFTI8S6XxTR53N4s7DgGU0YNkwYJlw4O38zcYKhFxrvTdFWDYmiy6jnlBeTEIROPB6fk3TnH9b1Zj1lmyEJOzJaO4aG0K_BC6obw48tdE7uxSGhOsJejrwborE3w7839_nNzN_AXcDG8yu5-_Bom-35iWBtj5_Nc7RXyG7O4o priority: 102 providerName: Springer Nature |
| Title | Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes |
| URI | https://link.springer.com/article/10.1007/s00705-021-04969-4 https://www.ncbi.nlm.nih.gov/pubmed/33533976 https://www.proquest.com/docview/2500177342 https://www.proquest.com/docview/2486158222 https://www.proquest.com/docview/2551990714 |
| Volume | 166 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdby2AvZd9z15Ub7G0z84diy08lCcnKxsIoDWRPRpbl1eA6qZ0M-pfu3-mdZLuMsrzEBJ_NWXfS_U66D8Y-FogB0M5R2i9Och6gzyqTRLsiU1woFamRqVPwYxGdL_m31WjVbbi1XVhlvyaahTpfK9oj_4KmGpUnDnlwtrlxqWsUna52LTQes0NTugz1OV4NDhfqr22wiS67KyJPdEkzJnWO6txQbjI60zyJEpf_a5geoM0HJ6XGAM2fsaMOOcLYivo5e6TrF-yJ7SV5-5L9vexDxmFdwJWmSOlt2cIU_pTNroU-6qoG2noFa8pcSmuofwMOb0nRvlULmwqJmzKT-L-sQVem7RcCUjAEcLEYA-WkAJVINjUJKjDR74AjtK6pPLJsgM4DWnxtDg3VhrVP23UWKH1m02rkCLmgqBDdsauAwuFrdXV7jS-1KcntK7aczy6n527XtcFV3BNbN8hFHGvloeeI2CAqCoV2WMcKBShGIhaeLGTu8SKXeeQpKZUfZpyjZ6SDQGquwtfsANnVbxkkSCTiMCtk7PMs5zKmUDoZ6VBnoogKh_m9yFLVlTSnzhpVOhRjNmJOUcypEXPKHfZpeGZjC3rspT7pNSHtJneb3quiwz4Mt3Fa0tjKWq93SMMFYkVCX3toEK0iGMBvc9gbq2UDS2GIOByhosM-92p3z8D_-T3ez-879jSwKu96_gk72DY7_R5B1TY7NTMHf8XUP2WH4_lksqDr11_fZ3idzBY_L_DuMhjfAY7OJ94 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9NADLdGJ8ReEP8pDDASPEFEmlyTywNCY2zq2FahqZP2ll0uFxapS0vTgvql-Dp8Hey7pBOa6NseqzpXp3bs3-X8swHeFIQBKM8x7ZcechHQnlUlifFkpoXUOtJ926fgeBgNTsXXs_7ZBvxuuTBcVtnGRBuo84nmd-QfKFWT88ShCD5Nf3g8NYpPV9sRGs4tDs3yF23Z6o8HX8i-b4Ngf2-0O_CaqQKeFr6ce0Eu49hon3Y2lLuiotCUJ0ys6QdkX8bSV4XKfVHkKo98rZTuhZkQhNxNECgjdEjr3oJNwYzWDmx-3ht-O1nFfkoIfXduITwZ-bKh6ViyHnfWYTY0bd9FEiWe-DcVXsO3185mbcrbvwd3G6yKO8657sOGqR7AbTe9cvkQ_ozaInWcFHhhuDZ7Xta4iz_L2aLGts6rQn7Ziy55ekykqL4jGbTk-uJxjdMxCc_KTNHnskIztoPGCAKjFcCT4Q4yCwa5KbPtgjBGW2-PZJNJxQ2Z1Qz5BKKmZXOccTdad7WL7MiEnWltSCPSgutQTKOuRi7Ar_TF8pIWdSTo-hGc3ohFH0OH1DVPARMSknGYFSruiSwXKubiPRWZ0GSyiIou9FqTpbppos6zPMbpqv2zNXNKZk6tmVPRhXera6auhcha6e3WE9ImnNTplfN34fXqawoE_N-qykwWJCMkoVPGe2tkCB8T_KB768IT52UrlcKQkD-B0y68b93uSoH_6_tsvb6v4M5gdHyUHh0MD5_DVuDc3_N729CZzxbmBUG6efayeY4Qzm_60f0L_Flg5w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VIhAXxG8xFBgkOIFVx97Y6wNCVUvUUogQaqXczHq9Sy0ZJ9gJKK_Gi_A6zOzarlBFbj1aGa_HmZmdb7zzw9hLgxgA_RyV_aKR8xBjVpmm2he54kKpWI1tn4JP0_jojH-YjWdb7HdfC0Nplf2eaDfqYq7oG_keumpUniTi4Z7p0iI-H07eLX74NEGKTlr7cRpORU70-heGb-3b40OU9aswnLw_PTjyuwkDvuKBWPphIZJEqwCjHPRjsTEKfYZOFD5MjEUiAmlkEXBTyCIOlJRqFOWcI4rXYSg1VxGue41dTyJEVWhLyWwI9tB23HDPKOC-iAPRFezYsj3qsUN10RjI8zROff6vU7yEdC-d0lrnN7nDbneoFfadmt1lW7q-x264OZbr--zPaZ-uDnMD55qytJdlCwfws2xWLfQZXzXQZ19wbtSnkor6G6BoS8o0rlpYVEjclLnE67IGXdmRYwiGwRLAl-k-UD0MUHtm2w-hApt5DyiReU2tmWUDdBbR4rIFNNSX1t3t9nig0p1Fq5Ej5IIyUnTHrgJKxa_V-fo7LurKodsH7OxK5PmQbSO7-hGDFIlEEuVGJiOeF1wmlMYnYx3pXJjYeGzUiyxTXTt1mupRZUMjaCvmDMWcWTFn3GOvh3sWrpnIRurdXhOybmNpswsz8NiL4WfcEui_lbWer5CGC8SphPw20CBSRiCC7-axHadlA0tRhDEAwlSPvenV7oKB__P7eDO_z9lNNNjs4_H05Am7FTrt94PRLtteNiv9FLHdMn9mjQjY16u22r8xeWOu |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+hepatitis+C+virus+infection+with+direct-acting+antivirals+plus+ribavirin+eliminates+viral+RNA+from+peripheral+blood+mononuclear+cells+and+reduces+virologic+relapse+in+diverse+hepatic+parenchymal+changes&rft.jtitle=Archives+of+virology&rft.au=Abd+Alla%2C+Mohamed+Darwish+Ahmed&rft.au=Dawood%2C+Reham+M&rft.au=Rashed%2C+Hassan+Abd+El-Hafeth&rft.au=Farrag%2C+Galal&rft.date=2021-04-01&rft.issn=1432-8798&rft.eissn=1432-8798&rft.volume=166&rft.issue=4&rft.spage=1071&rft_id=info:doi/10.1007%2Fs00705-021-04969-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-8608&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-8608&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-8608&client=summon |